Hangzhou Biotest Biotech ,Ltd. Receivables

Hangzhou Biotest Biotech ,Ltd. posts a receivables of $99M as of June 2026. That compares with $73M in the prior-year period — up 34.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Hangzhou Biotest Biotech ,Ltd.'s receivables was $73M. The latest reading is $99M — a 34.7% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Hangzhou Biotest Biotech ,Ltd.'s financial statement story. At $99M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 688767.SS's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Hangzhou Biotest Biotech ,Ltd.'s other metric pages and overview cover the third.

Judging Hangzhou Biotest Biotech ,Ltd. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $99M here, then scan peer and history charts to see if the gap is persistent.